Occupational exposure to conventional antineoplastic drugs: can it be further limited?

Nicolas Simon; Pascal Odou; Bertrand Décaudin; Pascal Bonnabry; Sandrine Fleury Souverain

doi:10.1136/ejhpharm-2019-002165

Occupational exposure to conventional antineoplastic drugs: can it be further limited?

Eur J Hosp Pharm. 2020 Sep;27(5):251-252. doi: 10.1136/ejhpharm-2019-002165. Epub 2019 Dec 16.

Authors

Nicolas Simon^{1

2}, Pascal Odou³, Bertrand Décaudin³, Pascal Bonnabry², Sandrine Fleury Souverain²

Affiliations

¹ Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France nicolas.simon@univ-lille.fr.
² Pharmacy, Geneva University Hospitals and School of Pharmaceutical Sciences, University Hospital of Geneva, University of Lausanne, Geneva, Switzerland.
³ Univ. Lille, CHU Lille, EA 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France.

No abstract available

Keywords: chemotherapy; compounding (individualised preparation); occupational & industrial medicine; production techniques and equipment; risk management.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / standards
Decontamination / methods*
Decontamination / standards
Health Personnel* / standards
Humans
Occupational Exposure / prevention & control*
Occupational Exposure / standards

Substances

Antineoplastic Agents